2 news items
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
KA
15 May 24
allocations expense as we transitioned to clinical trials in 2023 and ceased using our laboratory space, partially offset by higher activities for KVA12123
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
KA
21 Mar 24
development of KVA12123 as well as general corporate purposes, partially offset by $8.6 million net proceeds received from institutional and individual
- Prev
- 1
- Next